Disc Medicine Inc Ordinary Shares IRON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IRON is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $26.52
- Day Range
- $25.64–27.90
- 52-Week Range
- $25.60–77.60
- Bid/Ask
- $26.00 / $27.55
- Market Cap
- $679.96 Mil
- Volume/Avg
- 368,874 / 481,760
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 74
- Website
- https://www.discmedicine.com
Comparables
Valuation
|
Metric
|
IRON
|
VRDN
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.87 | 2.95 | 12.65 |
Price/Sales | — | 1,835.80 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
IRON
VRDN
CBAY
Financial Strength
|
Metric
|
IRON
|
VRDN
|
CBAY
|
|---|---|---|---|
Quick Ratio | 16.81 | 17.93 | 10.70 |
Current Ratio | 17.06 | 18.26 | 10.96 |
Interest Coverage | — | −137.76 | −5.27 |
Quick Ratio
IRON
VRDN
CBAY
Profitability
|
Metric
|
IRON
|
VRDN
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −22.91% | −42.76% | −30.06% |
Return on Equity (Normalized) | −24.27% | −82.42% | −51.97% |
Return on Invested Capital (Normalized) | −28.04% | −50.70% | −30.87% |
Return on Assets
IRON
VRDN
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cdwbwtdjv | Gpgl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rzbzktfh | Fsjvjnj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fxzvgshg | Hmdpyb | $97.8 Bil | |
MRNA
| Moderna Inc | Krpzfckpq | Qxlrf | $41.3 Bil | |
ARGX
| argenx SE ADR | Qbnfchvs | Xpcy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qlkwkysz | Xknrn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rtqsgct | Ppjxkqf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Myyldzjks | Clkfgz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qpwjctrl | Qwyrbf | $12.5 Bil | |
INCY
| Incyte Corp | Gkmgsggc | Gqpnjv | $11.6 Bil |